Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 222

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network

Russo, Mark W., Hoofnagle, Jay H., Gu, Jiezhun, Fontana, Robert J., Barnhart, Huiman, Kleiner, David E., Chalasani, Naga, Bonkovsky, Herbert L.·2014·Hepatology
DOI 10.1002/hep.27157PMC PMC4110177
Open this paper in CoChat — free account

Abstract

The HMG-CoA reductase inhibitors (statins) are widely prescribed for patients with hyperlipidemia and are generally well tolerated. Mild elevations in serum aminotransferases arise in up to 3% of treated patients, but clinically apparent drug-induced liver injury is rare. The aim of this study is to report the presenting features and outcomes of 22 patients with clinically apparent liver injury due to statins. Among 1,188 cases of drug-induced liver injury enrolled between 2004 and 2012 in a prospective registry by the U.S. Drug Induced Liver Injury Network, 22 were attributed to a statin. All patients were evaluated in a standard fashion and followed for at least 6 months after onset. The median age was 60 years (range 41-80), and 15 (68%) were female. The latency to onset of liver injury ranged from 34 days to 10 years (median = 155 days). Median peak levels were alanine aminotransferase 892 U/L, alkaline phosphatase 358 U/L, and total bilirubin 6.1 mg/dL. Nine patients presented with cholestatic hepatitis and 12 patients presented with hepatocellular injury, of which six had an autoimmune phenotype. Nine patients were hospitalized, four developed evidence of hepatic failure, and one died. All commonly used statins were implicated. Four patients developed chronic liver injury, of which three had an autoimmune phenotype of liver injury. Conclusion : Drug-induced liver injury from statins is rare and characterized by variable patterns of injury, a range of latencies to onset, autoimmune features in some cases, and persistent or chronic injury in 18% of patients, most of whom have an autoimmune phenotype. (Hepatology 2014;60:679–686)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.27157

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 16

  1. Serruys, 2002, Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention., JAMA, 287, 32153222, 10.1001/jama.287.24.3215 · DOI · Paper page
  2. Beltowski, 2009, Adverse effects of statinsmechanisms and consequences., Curr Drug Saf, 4, 209228, 10.2174/157488609789006949 · DOI
  3. Chalasani, 2005, Statins and hepatotoxicity: focus on patients with fatty liver., Hepatology, 41, 690, 10.1002/hep.20671 · DOI
  4. Russo, 2009, Druginduced liver injury associated with statins., Semin Liver Dis, 29, 412422, 10.1055/s-0029-1240010 · DOI
  5. Bjornsson, 2012, Hepatotoxicity associated with statins: reports of idiosyncratic liver injury postmarketing., J Hepatol, 56, 374380, 10.1016/j.jhep.2011.07.023 · DOI · Paper page
  6. Chalasani, 2008, Causes, clinical features, and outcomes from a prospective study of drug induced liver injury in the United States., Gastroenterology, 135, 19241934, 10.1053/j.gastro.2008.09.011 · DOI · Paper page
  7. Davern, 2011, Acute hepatitis E infection accounts for some cases of suspected druginduced liver injury., Gastroenterology, 141, 16651672, 10.1053/j.gastro.2011.07.051 · DOI
  8. Danan, 1993, Causality assessment of adverse reactions to drugsI. A novel method based on the conclusions of international consensus meetings: application to drug induced liver injuries., J Clin Epidemiol, 46, 13231330, 10.1016/0895-4356(93)90101-6 · DOI · Paper page
  9. Kleiner, 2014, Hepatic histological findings in suspected druginduced liver injury: systematic evaluation and clinical associations., Hepatology, 59, 661670, 10.1002/hep.26709 · DOI · Paper page
  10. Alla, 2006, Autoimmune hepatitis triggered by statins., J Clin Gastroenterol, 40, 757761, 10.1097/00004836-200609000-00018 · DOI
  11. Nakad, 1999, Atorvastatininduced hepatitis with the absence of crosstoxicity with simvastatin., Lancet, 353, 17631764, 10.1016/S0140-6736(99)00569-3 · DOI
  12. Charles, 2005, Evaluation of cases of severe statinrelated transaminitis within a large health maintenance organization., Am J Med, 118, 618624, 10.1016/j.amjmed.2005.02.008 · DOI
  13. Perger, 2003, Fatal liver failure with atorvastatin., J Hepatol, 39, 10951097, 10.1016/S0168-8278(03)00464-1 · DOI
  14. Sreenarasinhaiah, 2002, Multiorgan failure induced by atorvastatin., Am J Med, 113, 348349
  15. Ridruejo, 2002, Acute cholestatic hepatitis after reinitiating treatment with atorvastatin., J Hepatol, 37, 165166, 10.1016/S0168-8278(02)00092-2 · DOI
  16. Chen, 2007, Marked elevation of liver transaminases after highdose fluvastatin unmasks chronic hepatitis C: safety and rechallenge., Acta Neurol Taiwan, 16, 163167

Cited by

Metadata

Authors
Russo, M. W., Hoofnagle, J. H., Gu, J., Fontana, R. J., Barnhart, H., Kleiner, D. E., Chalasani, N., & Bonkovsky, H. L.
Venue
Hepatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2014-08
Volume
60
Issue
2
Pages
679-686
ISSN
0270-9139
DOI
10.1002/hep.27157
PMC
PMC4110177
Cited by
222
References
3
Language
en
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 396 d)
Funders
National Institutes of Health (1UO1DK065201,1UO1DK065193,1UO1DKO65184,1UO1DK065211,1UO1DK065238, and 1UO1DK06F5176)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.